Bharat Biotech has so far invested over ₹500 crores at risk from its own resources for product development, clinical trials and setting up of manufacturing facilities for Covaxin.

₹150 per Covaxin dose to Centre not sustainable in long run: Bharat Biotech

Special Correspondent
The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting vaccine supplies in the developing world.

Coronavirus | Novavax claims 90% efficacy for its vaccine

Sriram Lakshman

Other Articles